Review3 Biotech2025
Review in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Created, Not Engineered: Analyzing Human Gene Editing from a Catholic Anthropological and Moral Perspective.Journal of religion and health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, industrial biotechnology addresses diverse challenges, fostering environmental conservation, sustainable development, economic growth, and innovation. Currently, there are approximately 20,922 biotech companies worldwide, including 6,653 in the US, reflecting significant growth. The global biotech market is valued at $727.1 billion and is projected to expand at a compound annual growth rate of 7.4% by 2025. In India, industrial biotechnology holds promise, with about 3% of the global market share. The country has the highest number of FDA-approved manufacturing facilities outside the US, totaling 665 plants. This growth is driven by government support and a skilled workforce, with a focus on advancements in bioenergy, bio-based materials, and healthcare. Recent years have witnessed a surge in international demand for Indian vaccines and biopharmaceuticals, positioning the country as a leading hub for contract manufacturing and clinical trials. The country's bioeconomy, valued at $150 billion by 2023, is forecasted to double to $300 billion by 2030. This growth is supported by the government's BIRAC scheme, which has established 60 successful bio-incubation centers, further promoting innovation and entrepreneurship. India's bioeconomy basically consists of four segments: BioIndustrial ($72.6 billion, 48.09%), BioAgri ($12.44 billion, 8.24%), BioPharma ($53.8 billion, 35.65%), and BioServices ($12.1 billion, 8.02%), with biotech start-ups reaching 8,531 in 2023. This comprehensive review highlights the significant potential of industrial biotechnology in India by focusing on technological advancements, policy impacts, and market trends. It provides an overview of the current landscape, challenges, and future opportunities, and offers insights to guide strategic initiatives aimed at advancing the sector.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.